Here's What to Expect From Amgen’s Next Earnings Report

Company Overview - Amgen Inc. (AMGN) is a leading global biotechnology company with a market cap of $158.6 billion, headquartered in Thousand Oaks, California, focusing on innovative human therapeutics for serious illnesses, particularly in oncology, nephrology, cardiovascular disease, and inflammation [1] Earnings Expectations - Amgen is expected to release its fiscal Q3 2025 earnings results on November 4, with analysts predicting a profit of $5.01 per share, which represents a 10.2% decrease from $5.58 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast an EPS of $21.10, indicating a 6.4% increase from $19.84 in fiscal 2024 [3] Stock Performance - Over the past 52 weeks, Amgen's stock has declined by 8.4%, underperforming the S&P 500 Index, which gained 16.3%, and the Health Care Select Sector SPDR Fund, which saw a 6% dip [4] Recent Developments - On October 1, Amgen's shares surged by 6.4% following the announcement of a $650 million investment to expand its U.S. biologics manufacturing facility in Juncos, which is expected to create nearly 750 new jobs, emphasizing the company's commitment to U.S. biomanufacturing and global supply chain strength [5] Analyst Ratings - The consensus rating for AMGN stock is "Moderate Buy," with 33 analysts covering the stock, including 12 "Strong Buys," 2 "Moderate Buys," 16 "Holds," 1 "Moderate Sell," and 2 "Strong Sells." The average analyst price target for AMGN is $315.26, suggesting a potential upside of 6.7% from current levels [6]